Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After Autologous Hematopoietic Cell Transplant in Multiple Myeloma

NCT05820763 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05820763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05820763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After Autologous Hematopoietic Cell Transplant in Multiple Myeloma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
January 5, 2024
Completion date
January 31, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, myeloma-associated amyloidosis